The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans

Ju Hee Kang; Magdalena Korecka; Michal J. Figurski; Jon B. Toledo; Kaj Blennow; Henrik Zetterberg; Teresa Waligorska; Magdalena Brylska; Leona Fields; Nirali Shah; Holly Soares; Robert A. Dean; Hugo Vanderstichele; Ronald C. Petersen; Paul S. Aisen; Andrew J. Saykin; Michael W. Weiner; John Q. Trojanowski; Leslie M. Shaw

doi:10.1016/j.jalz.2015.05.003

The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans

Ju Hee Kang, Magdalena Korecka, Michal J. Figurski, Jon B. Toledo, Kaj Blennow, Henrik Zetterberg, Teresa Waligorska, Magdalena Brylska, Leona Fields, Nirali Shah, Holly Soares, Robert A. Dean, Hugo Vanderstichele, Ronald C. Petersen, Paul S. Aisen, Andrew J. Saykin, Michael W. Weiner, John Q. Trojanowski, Leslie M. Shaw

Research output: Contribution to journal › Review article › peer-review

39 Scopus citations

Abstract

Introduction We describe Alzheimer's Disease Neuroimaging Initiative (ADNI) Biomarker Core progress including: the Biobank; cerebrospinal fluid (CSF) amyloid beta (Aβ_1-42), t-tau, and p-tau₁₈₁ analytical performance, definition of Alzheimer's disease (AD) profile for plaque, and tangle burden detection and increased risk for progression to AD; AD disease heterogeneity; progress in standardization; and new studies using ADNI biofluids. Methods Review publications authored or coauthored by ADNI Biomarker core faculty and selected non-ADNI studies to deepen the understanding and interpretation of CSF Aβ_1-42, t-tau, and p-tau₁₈₁ data. Results CSF AD biomarker measurements with the qualified AlzBio3 immunoassay detects neuropathologic AD hallmarks in preclinical and prodromal disease stages, based on CSF studies in non-ADNI living subjects followed by the autopsy confirmation of AD. Collaboration across ADNI cores generated the temporal ordering model of AD biomarkers varying across individuals because of genetic/environmental factors that increase/decrease resilience to AD pathologies. Discussion Further studies will refine this model and enable the use of biomarkers studied in ADNI clinically and in disease-modifying therapeutic trials.

Original language	English (US)
Pages (from-to)	772-791
Number of pages	20
Journal	Alzheimer's and Dementia
Volume	11
Issue number	7
DOIs	https://doi.org/10.1016/j.jalz.2015.05.003
State	Published - Jul 1 2015

Keywords

ADNI
Alzheimer's disease
Aβ
Biomarkers
Cerebrospinal fluid
Disease-modifying therapy
Immunoassay
Mild cognitive impairment
Plasma
Tau

ASJC Scopus subject areas

Clinical Neurology
Geriatrics and Gerontology
Psychiatry and Mental health
Cellular and Molecular Neuroscience
Health Policy
Developmental Neuroscience
Epidemiology

Access to Document

10.1016/j.jalz.2015.05.003

Cite this

Kang, J. H., Korecka, M., Figurski, M. J., Toledo, J. B., Blennow, K., Zetterberg, H., Waligorska, T., Brylska, M., Fields, L., Shah, N., Soares, H., Dean, R. A., Vanderstichele, H., Petersen, R. C., Aisen, P. S., Saykin, A. J., Weiner, M. W., Trojanowski, J. Q., & Shaw, L. M. (2015). The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans. Alzheimer's and Dementia, 11(7), 772-791. https://doi.org/10.1016/j.jalz.2015.05.003

Kang, JH, Korecka, M, Figurski, MJ, Toledo, JB, Blennow, K, Zetterberg, H, Waligorska, T, Brylska, M, Fields, L, Shah, N, Soares, H, Dean, RA, Vanderstichele, H, Petersen, RC, Aisen, PS, Saykin, AJ, Weiner, MW, Trojanowski, JQ & Shaw, LM 2015, 'The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans', Alzheimer's and Dementia, vol. 11, no. 7, pp. 772-791. https://doi.org/10.1016/j.jalz.2015.05.003

@article{52915160e6ca4ec5afb42ea791b3a10e,

title = "The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans",

abstract = "Introduction We describe Alzheimer's Disease Neuroimaging Initiative (ADNI) Biomarker Core progress including: the Biobank; cerebrospinal fluid (CSF) amyloid beta (Aβ1-42), t-tau, and p-tau181 analytical performance, definition of Alzheimer's disease (AD) profile for plaque, and tangle burden detection and increased risk for progression to AD; AD disease heterogeneity; progress in standardization; and new studies using ADNI biofluids. Methods Review publications authored or coauthored by ADNI Biomarker core faculty and selected non-ADNI studies to deepen the understanding and interpretation of CSF Aβ1-42, t-tau, and p-tau181 data. Results CSF AD biomarker measurements with the qualified AlzBio3 immunoassay detects neuropathologic AD hallmarks in preclinical and prodromal disease stages, based on CSF studies in non-ADNI living subjects followed by the autopsy confirmation of AD. Collaboration across ADNI cores generated the temporal ordering model of AD biomarkers varying across individuals because of genetic/environmental factors that increase/decrease resilience to AD pathologies. Discussion Further studies will refine this model and enable the use of biomarkers studied in ADNI clinically and in disease-modifying therapeutic trials.",

keywords = "ADNI, Alzheimer's disease, Aβ, Biomarkers, Cerebrospinal fluid, Disease-modifying therapy, Immunoassay, Mild cognitive impairment, Plasma, Tau",

author = "Kang, {Ju Hee} and Magdalena Korecka and Figurski, {Michal J.} and Toledo, {Jon B.} and Kaj Blennow and Henrik Zetterberg and Teresa Waligorska and Magdalena Brylska and Leona Fields and Nirali Shah and Holly Soares and Dean, {Robert A.} and Hugo Vanderstichele and Petersen, {Ronald C.} and Aisen, {Paul S.} and Saykin, {Andrew J.} and Weiner, {Michael W.} and Trojanowski, {John Q.} and Shaw, {Leslie M.}",

note = "Publisher Copyright: {\textcopyright} 2015 Published by Elsevier Inc.",

year = "2015",

month = jul,

day = "1",

doi = "10.1016/j.jalz.2015.05.003",

language = "English (US)",

volume = "11",

pages = "772--791",

journal = "Alzheimer's and Dementia",

issn = "1552-5260",

publisher = "Elsevier Inc.",

number = "7",

}

TY - JOUR

T1 - The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core

T2 - A review of progress and plans

AU - Kang, Ju Hee

AU - Korecka, Magdalena

AU - Figurski, Michal J.

AU - Toledo, Jon B.

AU - Blennow, Kaj

AU - Zetterberg, Henrik

AU - Waligorska, Teresa

AU - Brylska, Magdalena

AU - Fields, Leona

AU - Shah, Nirali

AU - Soares, Holly

AU - Dean, Robert A.

AU - Vanderstichele, Hugo

AU - Petersen, Ronald C.

AU - Aisen, Paul S.

AU - Saykin, Andrew J.

AU - Weiner, Michael W.

AU - Trojanowski, John Q.

AU - Shaw, Leslie M.

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Introduction We describe Alzheimer's Disease Neuroimaging Initiative (ADNI) Biomarker Core progress including: the Biobank; cerebrospinal fluid (CSF) amyloid beta (Aβ1-42), t-tau, and p-tau181 analytical performance, definition of Alzheimer's disease (AD) profile for plaque, and tangle burden detection and increased risk for progression to AD; AD disease heterogeneity; progress in standardization; and new studies using ADNI biofluids. Methods Review publications authored or coauthored by ADNI Biomarker core faculty and selected non-ADNI studies to deepen the understanding and interpretation of CSF Aβ1-42, t-tau, and p-tau181 data. Results CSF AD biomarker measurements with the qualified AlzBio3 immunoassay detects neuropathologic AD hallmarks in preclinical and prodromal disease stages, based on CSF studies in non-ADNI living subjects followed by the autopsy confirmation of AD. Collaboration across ADNI cores generated the temporal ordering model of AD biomarkers varying across individuals because of genetic/environmental factors that increase/decrease resilience to AD pathologies. Discussion Further studies will refine this model and enable the use of biomarkers studied in ADNI clinically and in disease-modifying therapeutic trials.

AB - Introduction We describe Alzheimer's Disease Neuroimaging Initiative (ADNI) Biomarker Core progress including: the Biobank; cerebrospinal fluid (CSF) amyloid beta (Aβ1-42), t-tau, and p-tau181 analytical performance, definition of Alzheimer's disease (AD) profile for plaque, and tangle burden detection and increased risk for progression to AD; AD disease heterogeneity; progress in standardization; and new studies using ADNI biofluids. Methods Review publications authored or coauthored by ADNI Biomarker core faculty and selected non-ADNI studies to deepen the understanding and interpretation of CSF Aβ1-42, t-tau, and p-tau181 data. Results CSF AD biomarker measurements with the qualified AlzBio3 immunoassay detects neuropathologic AD hallmarks in preclinical and prodromal disease stages, based on CSF studies in non-ADNI living subjects followed by the autopsy confirmation of AD. Collaboration across ADNI cores generated the temporal ordering model of AD biomarkers varying across individuals because of genetic/environmental factors that increase/decrease resilience to AD pathologies. Discussion Further studies will refine this model and enable the use of biomarkers studied in ADNI clinically and in disease-modifying therapeutic trials.

KW - ADNI

KW - Alzheimer's disease

KW - Aβ

KW - Biomarkers

KW - Cerebrospinal fluid

KW - Disease-modifying therapy

KW - Immunoassay

KW - Mild cognitive impairment

KW - Plasma

KW - Tau

UR - http://www.scopus.com/inward/record.url?scp=84937548717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937548717&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2015.05.003

DO - 10.1016/j.jalz.2015.05.003

M3 - Review article

C2 - 26194312

AN - SCOPUS:84937548717

SN - 1552-5260

VL - 11

SP - 772

EP - 791

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

IS - 7

ER -

The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this